Literature DB >> 27048286

Inhibition of protein methylesterase 1 decreased cancerous phenotypes in endometrial adenocarcinoma cell lines and xenograft tumor models.

Michelle Pusey1, Sophie Bail1, Yan Xu2, Olesia Buiakova2, Mariya Nestor3, Jing-Jing Yang3, Lyndi M Rice4.   

Abstract

Protein methylesterase 1 (PME-1) promotes cancerous phenotypes through the demethylation and inactivation of protein phosphatase 2A. We previously demonstrated that PME-1 overexpression promotes Akt, ERK, and may promote Wnt signaling and increases tumor burden in a xenograft model of endometrial cancer. Here, we show that covalent PME-1 inhibitors decrease cell proliferation and invasive growth in vitro but have no effect in vivo at the concentrations tested; however, depletion of PME-1 with shRNA in an endometrial cancer xenograft model significantly reduced tumor growth. Thus, discovery of more potent PME-1 inhibitors may be beneficial for the treatment of endometrial cancer.

Entities:  

Keywords:  ABL-127; Endometrial cancer; PME-1; PP2A

Mesh:

Substances:

Year:  2016        PMID: 27048286     DOI: 10.1007/s13277-016-5036-8

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  37 in total

1.  Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery.

Authors:  Mei-Chu Lo; Ann Aulabaugh; Guixian Jin; Rebecca Cowling; Jonathan Bard; Michael Malamas; George Ellestad
Journal:  Anal Biochem       Date:  2004-09-01       Impact factor: 3.365

2.  Protein phosphatase 2A regulates life and death decisions via Akt in a context-dependent manner.

Authors:  Shaida Andrabi; Ole V Gjoerup; Jennifer A Kean; Thomas M Roberts; Brian Schaffhausen
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-15       Impact factor: 11.205

Review 3.  From promiscuity to precision: protein phosphatases get a makeover.

Authors:  David M Virshup; Shirish Shenolikar
Journal:  Mol Cell       Date:  2009-03-13       Impact factor: 17.970

Review 4.  Involvement of PP2A in viral and cellular transformation.

Authors:  Jason D Arroyo; William C Hahn
Journal:  Oncogene       Date:  2005-11-21       Impact factor: 9.867

5.  Neuroprotective and anti-inflammatory properties of a coffee component in the MPTP model of Parkinson's disease.

Authors:  Kang-Woo Lee; Joo-Young Im; Jong-Min Woo; Hilary Grosso; Yoon-Seong Kim; Ana Clara Cristovao; Patricia K Sonsalla; David S Schuster; Marla M Jalbut; Jose R Fernandez; Michael Voronkov; Eunsung Junn; Steven P Braithwaite; Jeffry B Stock; M Maral Mouradian
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

6.  DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination.

Authors:  Christopher Korch; Monique A Spillman; Twila A Jackson; Britta M Jacobsen; Susan K Murphy; Bruce A Lessey; V Craig Jordan; Andrew P Bradford
Journal:  Gynecol Oncol       Date:  2012-06-16       Impact factor: 5.482

7.  PME-1 protects extracellular signal-regulated kinase pathway activity from protein phosphatase 2A-mediated inactivation in human malignant glioma.

Authors:  Pietri Puustinen; Melissa R Junttila; Sari Vanhatupa; Anna A Sablina; Melissa E Hector; Kaisa Teittinen; Olayinka Raheem; Kirsi Ketola; Shujun Lin; Juergen Kast; Hannu Haapasalo; William C Hahn; Jukka Westermarck
Journal:  Cancer Res       Date:  2009-03-17       Impact factor: 12.701

Review 8.  SV40 small T antigen and PP2A phosphatase in cell transformation.

Authors:  Anna A Sablina; William C Hahn
Journal:  Cancer Metastasis Rev       Date:  2008-06       Impact factor: 9.264

9.  A protein phosphatase methylesterase (PME-1) is one of several novel proteins stably associating with two inactive mutants of protein phosphatase 2A.

Authors:  E Ogris; X Du; K C Nelson; E K Mak; X X Yu; W S Lane; D C Pallas
Journal:  J Biol Chem       Date:  1999-05-14       Impact factor: 5.157

10.  Structural mechanism of demethylation and inactivation of protein phosphatase 2A.

Authors:  Yongna Xing; Zhu Li; Yu Chen; Jeffry B Stock; Philip D Jeffrey; Yigong Shi
Journal:  Cell       Date:  2008-04-04       Impact factor: 41.582

View more
  3 in total

Review 1.  Deregulation of the protein phosphatase 2A, PP2A in cancer: complexity and therapeutic options.

Authors:  Godfrey Grech; Shawn Baldacchino; Christian Saliba; Maria Pia Grixti; Robert Gauci; Vanessa Petroni; Anthony G Fenech; Christian Scerri
Journal:  Tumour Biol       Date:  2016-07-21

Review 2.  Targeted Therapies in Type II Endometrial Cancers: Too Little, but Not Too Late.

Authors:  Michiel Remmerie; Veerle Janssens
Journal:  Int J Mol Sci       Date:  2018-08-13       Impact factor: 5.923

Review 3.  Protein phosphatase 2A as a therapeutic target in inflammation and neurodegeneration.

Authors:  Andrew R Clark; Michael Ohlmeyer
Journal:  Pharmacol Ther       Date:  2019-06-01       Impact factor: 12.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.